How much could a monthly dose of semaglutide cost globally?

Injectable semaglutide could be produced for approximately $3 per monthly dose, with newer pill formulations potentially costing around $16 per month.

When will patents for semaglutide expire?

Core patents for semaglutide are scheduled to expire in 10 countries, including Brazil, China, and India, starting from March 21.

Which regions could benefit most from cheaper semaglutide?

Approximately 160 countries, many in Africa and other low- and middle-income regions, could gain access, where a significant portion of the global type 2 diabetes and obesity cases reside.

Home / Health / Ozempic/Wegovy for $3: Global Access Looms

Ozempic/Wegovy for $3: Global Access Looms

6 Mar

•

Summary

Semaglutide could be produced for $3 per monthly dose.
Patents expire soon in 10 countries, opening generic competition.
160 countries with high diabetes/obesity rates may gain access.

Ozempic/Wegovy for $3: Global Access Looms

Injectable semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could soon be produced for approximately $3 per monthly dose, according to new analysis. This price point has the potential to make the essential medicine accessible to millions worldwide, particularly in lower-income nations. Core patents for semaglutide are set to expire in 10 countries, including Brazil, China, India, and South Africa, beginning March 21, paving the way for generic competition.

Researchers identified an additional 150 countries, including most of Africa, where patents have not been filed. These 160 countries collectively account for 69% of the global type 2 diabetes population and 84% of individuals living with obesity. This breakthrough offers a model for widespread access similar to that seen with HIV and malaria treatments, where affordable generic options ensure sustainable supply.